Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Genetics of Hemophilia Mystery Solved

By BiotechDaily International staff writers
Posted on 25 Mar 2013
The third and final missing piece in the genetic puzzle of an unusual form of hemophilia has been found which could help improve the comprehension of other blood-clotting conditions such as thrombosis.

Hemophilia B Leyden is an X-linked recessive blood-clotting disorder that affects approximately 1 in every 30,000 males and it is also infamously known as the ‘‘royal disease’’ because it afflicted European royal families descended from Queen Victoria.

Geneticists at the University of New South Wales (Kensington, Australia) studied mutations that arise in coagulation factor IX (F9). Mutations within the F9 promoter are associated with the hemophilia B Leyden subtype in which symptoms ameliorate after puberty. Symptoms improve in young men after puberty because a different protein that responds to the hormone testosterone is able to bind to the DNA and boost the gene’s production of clotting factor IX. The disease affects about 80 families worldwide.

The scientists established that the missing regulators in hemophilia B Leyden are the ONECUT transcription factors ONECUT1 and ONECUT2. These proteins bind to the proximal promoter and drive expression of F9. ONECUT1 is also known as hepatocyte nuclear factor 6 (HNF6), while ONECUT2 is known either as hepatocyte nuclear factor 6-beta or one cut homeobox 2. The different Leyden mutations disrupt ONECUT binding to varying degrees in a manner that correlates well with their clinical severities.

Merlin Crossley, PhD, the dean of science at University of New South Wales and senior author of the study, said, “Science is advanced by people who get caught up in puzzles that are important to them and they never forget them. Curious investigators never give up.” Professor Crossley had previously found the two sets of mutations that prevent two key proteins from attaching to the DNA, which turns the gene off as a result. The study was published on March 7, 2013, in the American Journal of Human Genetics.

Related Links:

University of New South Wales





Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.